How did the company’s operating expenses and R&D spend change versus the prior quarter and the same quarter last year? | DARE (Aug 07, 2025) | Candlesense
DARE

How did the company’s operating expenses and R&D spend change versus the prior quarter and the same quarter last year?

I’m sorry, but the excerpt you provided only announces the upcoming earnings‑release conference call and does not contain the actual financial figures for operating expenses or research‑and‑development (R&D) spend. Because those numbers aren’t included in the news text you shared, I can’t tell you how the company’s operating expenses or R&D spend changed compared with the prior quarter or the same quarter a year ago.

To obtain that information you would need to look at the detailed earnings release or the accompanying financial tables that Dare Bioscience will provide during the August 14, 2025 conference call (or in the related SEC filing, such as a Form 10‑Q). Those documents will break out:

  • Operating expenses for the quarter ended June 30, 2025, along with a side‑by‑side comparison to Q2 2025 (the prior quarter) and Q2 2024 (the same quarter last year).
  • R&D expenses with the same comparative figures.

If you can locate the full press release, earnings presentation, or the 10‑Q filing, I’d be happy to help you interpret the numbers once you have them.

Other Questions About This News

How did management’s commentary address competitive threats and market share trends in the women’s‑health biopharma space? Did the earnings call reveal any changes to the shareholder return policy (dividends, share buybacks, or stock‑based compensation)? Did the company announce any new product milestones or regulatory updates that could affect future sales? How did the Q2 2025 revenue and earnings per share compare to Wall Street consensus estimates? How does the current cash balance and runway compare to the company’s stated runway and financing needs? What guidance is management providing for Q3 and full‑year 2025 revenue, EPS, and cash flow? What is the status of any debt or convertible securities, and are there any upcoming maturities or refinancing plans? What were the key drivers of any revenue growth or decline (e.g., product launches, licensing deals, and geographic performance)? What were the latest updates on the company’s pipeline in women’s health, and how might they affect long‑term valuation? Are there any upcoming catalysts (e.g., IND filings, Phase III trial readouts, or partnership announcements) that could move the stock? What is the analyst consensus following the release, and how are major institutions altering their positions?